Duration of Apixaban for Non-Occlusive DVT
All patients with non-occlusive DVT should receive at least 3 months of therapeutic anticoagulation with apixaban (10 mg twice daily for 7 days, then 5 mg twice daily), after which you must assess whether the DVT was provoked or unprovoked to determine if extended-phase anticoagulation is warranted 1, 2.
Initial Treatment Phase (First 3 Months)
The standard treatment regimen for non-occlusive DVT follows the same protocol as occlusive DVT 2:
- Days 1-7: Apixaban 10 mg orally twice daily
- Months 1-3: Apixaban 5 mg orally twice daily
This 3-month treatment phase is strongly recommended for all acute VTE regardless of thrombus burden 1.
Decision Point at 3 Months: Provoked vs Unprovoked
After completing 3 months of anticoagulation, the critical decision is whether to continue extended-phase therapy. This depends entirely on the presence or absence of provoking factors 1:
STOP anticoagulation if:
- Major transient risk factor (e.g., surgery, major trauma, hospitalization with immobility >3 days): Do NOT offer extended therapy (strong recommendation) 1
- Minor transient risk factor (e.g., minor injury, estrogen therapy, prolonged travel): Generally do NOT offer extended therapy (weak recommendation) 1
CONTINUE anticoagulation if:
- Unprovoked DVT (no identifiable risk factor): Offer extended-phase anticoagulation (strong recommendation) 1
- Persistent risk factors (active cancer, ongoing immobility, known thrombophilia): Offer extended-phase anticoagulation (strong recommendation) 1
- Provoked DVT with enduring risk factors: Recent high-quality evidence shows reduced-dose apixaban significantly reduces recurrence (1.3% vs 10.0% with placebo, P<0.001) with minimal bleeding risk 3
Extended-Phase Anticoagulation Protocol
If extended therapy is indicated, use reduced-dose apixaban 2.5 mg twice daily rather than full-dose 5 mg twice daily (weak recommendation) 1, 2. This reduced dose:
- Maintains efficacy for preventing recurrent VTE 1, 3
- Reduces bleeding complications compared to full-dose therapy 4
- Is superior to aspirin or no therapy for secondary prevention 1
Duration of Extended Therapy
Extended-phase anticoagulation does not have a predefined stop date 1. However:
- Reassess annually and with any significant health status changes 1
- Clinical trial data support safety for 2-4 years of extended therapy 1
- Beyond 4 years, the risk-benefit balance becomes uncertain 1
- Balance individual bleeding risk against recurrence risk at each reassessment
Special Considerations
Active cancer patients: Should receive extended anticoagulation at least until cancer resolution. Recent evidence supports reduced-dose apixaban (2.5 mg twice daily) as noninferior to full-dose with lower bleeding rates in cancer-associated VTE 4.
Patient preference matters: The recommendation to offer extended therapy does not mean all patients must accept it. Bleeding risk, quality of life concerns, and patient values should influence the final decision 1.
Common Pitfalls to Avoid
- Don't assume non-occlusive = less serious: Non-occlusive DVT carries similar recurrence risk as occlusive DVT when unprovoked; treat duration the same way
- Don't use full-dose indefinitely: Switch to reduced-dose (2.5 mg twice daily) for extended therapy 1, 2
- Don't forget the 3-month checkpoint: This is when you must actively decide about extended therapy, not passively continue
- Don't stop abruptly without transition: If discontinuing after extended therapy, consider aspirin 81-325 mg daily for continued (though inferior) VTE prevention 1
The key algorithmic decision is straightforward: 3 months for everyone → assess provocation → stop if provoked by transient factors, continue with reduced-dose if unprovoked or persistent risk factors present.